Eikonizo Therapeutics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Eikonizo Therapeutics is a private, preclinical-stage biotech focused on selective HDAC6 inhibitors. Its lead CNS candidate, EKZ-102, is in IND-enabling studies for ALS, with plans to expand to other neurodegenerative diseases. The company is also developing peripheral HDAC6 inhibitors for cardiorenal indications like ADPKD and diabetic nephropathy, leveraging a platform designed for high selectivity and CNS penetrance to minimize side effects.

Neurodegenerative DiseasesCardiorenal Diseases

Technology Platform

Platform for developing highly selective, brain-penetrant and peripheral small molecule inhibitors of HDAC6, targeting dual mechanisms of intracellular transport and proteostasis.

Funding History

1

SeedUndisclosedUndisclosedJun 15, 2023

Opportunities

The large, underserved patient populations in neurodegenerative and cardiorenal diseases represent multi-billion dollar markets.

Success with its selective HDAC6 platform could establish a new therapeutic class for chronic diseases beyond oncology, offering significant first-mover potential in specific indications like ALS.

Risk Factors

High scientific risk that the novel dual-mechanism approach will translate to human efficacy.

Financial and operational risk associated with transitioning a preclinical, private company into clinical trials.

Competition from other entities developing HDAC6 inhibitors.

Competitive Landscape

HDAC6 is a competitive target with several biotech and pharmaceutical companies investigating inhibitors, primarily in oncology. Eikonizo's differentiation lies in its focus on high selectivity for HDAC6 (to avoid side effects) and application in chronic neurodegenerative/cardiorenal diseases, rather than cancer. It will compete with other neurology-focused HDAC6 programs.

More companies in United States →